A Phase I/II Study of AZD0466 as Monotherapy or in Combination with Anticancer Agents in Advanced Non-Hodgkin Lymphoma

Trial Identifier: D8242C00001
Sponsor: AstraZeneca
NCTID:: NCT05205161
Start Date: July 2022
Primary Completion Date: October 2024
Study Completion Date: May 2025
Condition: Non-Hodgkin's Lymphoma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Greenslopes, AU, 4120
AU Heidelberg, AU, 3084
CA, ON Toronto, ON, CA, M5G 2M9
ES Barcelona, ES, 08036
ES Barcelona, ES, 8035
ES Madrid, ES, 28027
ES Palma de Mallorca, ES, 07010
ES Pamplona, ES, 31008
ES Salamanca, ES, 37007
FR Nantes, FR, 44000
FR Poitiers, FR, 86021
IT Bologna, IT, 40138
IT Porto, IT, 4200-072
IT Roma, IT, 00144
KR Seoul, KR, 03080
KR Seoul, KR, 6591
KR Seoul, KR, 06351
KR Seoul, KR, 03722
PT Lisboa, PT, 1649-035
PT Porto, PT, 4200-072
US, CA Duarte, CA, US, 91010
US, MD Baltimore, MD, US, 21231
US, MN Rochester, MN, US, 55905
US, NC Concord, NC, US, 28025
US, NY Buffalo, NY, US, 14263
US, OH Canton, OH, US, 44718
US, TX Houston, TX, US, 77030
US, VA Richmond, VA, US, 23298